Section 3(d) strikes again in GSK India patent defeat

India’s Intellectual Property Appeal Board (IPAB) has revoked a patent covering GlaxoSmithKline’s (GSK) breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

Asia

Novo Nordisk India strategy suffers semaglutide patent setback

4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

Asia

WIPR Rankings reveals the go-to firms and attorneys for China patent work

7 November 2025 Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision

Section 3(d) strikes again in GSK India patent defeat

More on this story

Editor's picks

Editor's picks

More features